News for Viking Therapeutics, Inc. (VKTX)

Market Analysis by covering: Eli Lilly and Company, Novo Nordisk A/S, Viking Therapeutics Inc. Read 's Market Analysis on Investing.com

B. Riley has adjusted its price target for Viking Therapeutics (VKTX), lowering it from $96 to $85. Despite this adjustment, the firm maintains a Buy rating on

Viking's Q1 earnings show no revenue, increased R&D spending, and a substantial cash reserve, positioning it well for future trials. Read more about VKTX stock here.

Research and Development Expenses: $41.4 million for Q1 2025, up from $24.1 million in Q1 2024.General and Administrative Expenses: $14.1 million for Q1 2025,

Highlights: Viking Therapeutics Inc. (VKTX) is gaining attention due to potential acquisition interest and promising drug developments. Analysts project

Viking Therapeutics is making significant strides in obesity treatment with its drug VK2735. Analysts suggest a substantial potential upside for VKTX st

We recently published a list of 20 Takeover Rumors Hedge Funds Are Buying. In this article, we are going to take a look at where Viking Therapeutics, Inc.

Key Takeaways: Viking Therapeutics faces increased net losses due to significant research and development expenses. The company's stock holds substantial

Summary Viking Therapeutics Inc (VKTX), a clinical-stage biopharmaceutical company specializing in metabolic and endocrine disorder therapies, released its fina

PR NewswireSAN DIEGO, April 23, 2025 Conference call scheduled for 4:30 p.m. ET todayPhase 3 Trials for Subcutaneous VK2735 Expected to Begin 2Q25Phase 2 V

S&P 500 futures are up 21 points, Nasdaq 100 futures have increased by 123 points, while Dow Jones Industrial Average futures have dropped by 583 points.Future

ZeroHedge - On a long enough timeline, the survival rate for everyone drops to zero

Market Overview The stock market started the week with gains. The S&P 500 experienced an early surge, trading up as much as 1.8%. However, it settled 0.8% highe

Mubasher: The main indexes of Wall Street rose on Monday, 14 April, on the back of gains in technology stocks after the White House exempted smartphones and com...

Pfizer bows, but is not entirely out of the GLP-1 race.

U.S. stock futures were higher this morning, with the Dow futures gaining around 400 points on Friday. Shares of Apple Inc. AAPL fell sharply in today's pre-ma...

ZeroHedge - On a long enough timeline, the survival rate for everyone drops to zero

Three Motley Fool contributors think they've identified magnificent stocks that could double or more by 2030. Here's why they picked CRISPR Therapeutics (NASDAQ: CRSP), Summit Therapeutics (NASDAQ: SMMT), and Viking Therapeutics (NASDAQ: VKTX) as stocks worth buying now. Prosper Junior Bakiny (CRISPR Therapeutics): Despite creating Casgevy, the first CRISPR-based gene-editing medicine to earn regulatory approval, CRISPR Therapeutics has not performed well in the past year and a half since hitting that milestone.

In the latest trading session, Viking Therapeutics, Inc. (VKTX) closed at $23.91, marking a -0.99% move from the previous day.